Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NSC117079 is an inhibitor of PHLPP.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 987 | 5日内发货 | ||
5 mg | ¥ 1,810 | 5日内发货 | ||
25 mg | ¥ 7,380 | 6-8周 | ||
50 mg | ¥ 9,590 | 6-8周 | ||
100 mg | ¥ 16,200 | 6-8周 |
产品描述 | NSC117079 is an inhibitor of PHLPP. |
体外活性 | PHLPP inhibitors (NSC117079 and NSC45586;?benzoic acid, 5-[2-[4-[2-(2,4-diamino-5-methylphenyl)diazenyl]phenyl]diazenyl]-2-hydroxy-,sodium salt.) in rat cortical neurons and astrocytes and compared the biochemical response of these agents with short hairpin RNA (shRNA)-mediated PHLPP1 knockdown (KD).?In neurons, both PHLPP1 KD and experimental PHLPP inhibitors activated AKT and ameliorated staurosporine (STS)-induced cell death.?Unexpectedly, in astrocytes, both inhibitors blocked AKT activation, and NSC117079 reduced viability.?Only PHLPP2 KD mimicked PHLPP inhibitors on astrocyte biochemistry.?This suggests that these inhibitors could have possible detrimental effects on astrocytes by blocking novel PHLPP2-mediated prosurvival signaling mechanisms. |
体内活性 | Animals treated with the Phlpp inhibitor seven weeks after injury maintain normal activity levels, while those in the control group travel shorter distances and are less active three months after the joint injury.?NSC117079 also increases production of cartilage extracellular matrix components (glycosaminoglycans and aggrecan) in over 90% of human articular cartilage explants from osteoarthritis patients and increased phosphorylation of Phlpp1 substrates (AKT2, ERK1/2 and PKC) in human articular chondrocytes.A single intraarticular injection of the Phlpp inhibitor NSC117079 attenuates mechanical allodynia and slows articular cartilage degradation in joints with a destabilized meniscus[1]. |
分子量 | 473.48 |
分子式 | C20H15N3O7S2 |
CAS No. | 500363-63-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (105.60 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.112 mL | 10.5601 mL | 21.1202 mL | 52.8005 mL |
5 mM | 0.4224 mL | 2.112 mL | 4.224 mL | 10.5601 mL | |
10 mM | 0.2112 mL | 1.056 mL | 2.112 mL | 5.2801 mL | |
20 mM | 0.1056 mL | 0.528 mL | 1.056 mL | 2.64 mL | |
50 mM | 0.0422 mL | 0.2112 mL | 0.4224 mL | 1.056 mL | |
100 mM | 0.0211 mL | 0.1056 mL | 0.2112 mL | 0.528 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NSC117079 500363-63-3 Others NSC-117079 NSC 117079 Inhibitor inhibitor inhibit